,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['mbc', 'destiny-breast03', 'breast']
 destiny-breast03 trial - update safety analysis: no new aes were observed for t-dxd in patients with her+ #mbc, in particular no additional g3 adjudicated ild/pneumonitis event were observed. #asco22 #bcareporter 